A phase 3 trial shows a personalized mRNA vaccine cut melanoma recurrence or death risk by 42% when added to pembrolizumab.
Posts tagged as “clinical trial”
A personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma returning or death by 42% in a phase III trial.
Early studies in humans and mice suggest GLP‑1 medications may modestly reduce biological age, but researchers caution that findings are preliminary.
A study of nearly 200,000 adults found that eating after dinner or near bedtime is associated with a 20‑30% increase in fatty liver disease and cirrhosis risk.
Early human trials of the CBL-514 injection showed a 12% average reduction in dangerous visceral fat, alongside weight loss and improvements in blood pressure and cholesterol.
A ten‑patient trial of an optogenetic gene therapy demonstrated safety and modest gains in light sensitivity for people with advanced retinitis pigmentosa.
In a phase 3 study of 2,339 adults, weekly retatrutide injections produced up to 25% average weight loss after 80 weeks and improved knee pain and sleep apnea.
A small study of the RAS‑targeting drug daraxonrasib reported tumor shrinkage in over 30% of patients with KRAS‑mutated non‑small‑cell lung cancer.
A clinical trial for potential Ebola treatments has commenced in the Democratic Republic of Congo, with the World Health Organization announcing the enrollment of the first patient.
A groundbreaking therapy aimed at reversing cellular aging has been administered to the first human participant in a world-first clinical trial, marking a significant milestone in longevity research.